{"id":"W4399737488","doi":"10.1200/jco.2024.42.16_suppl.3091","title":"Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after <sup>177</sup>Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Somatostatin; Neuroendocrine tumors; Phase (matter); Internal medicine; Somatostatin Analogue; Phases of clinical research; Lanreotide; Oncology; Clinical trial; Cancer research; Pharmacology; Octreotide; Growth hormone; Hormone; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001733774,0.0002591418,0.00181663,0.0004387638,0.00004755608,0.00002828422,0.0002379159,0.0000405174,0.0001031595],"category_scores_gemma":[0.005333816,0.000162585,0.0005427301,0.0004816784,0.0006762053,0.0003150026,0.0001110294,0.001579563,0.000001895503],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001252518,"about_ca_system_score_gemma":0.001011212,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001505537,"about_ca_topic_score_gemma":0.00002142865,"domain_scores_codex":[0.9934254,0.001239725,0.00373764,0.0003618341,0.0007646504,0.0004707472],"domain_scores_gemma":[0.9950434,0.002503996,0.001552413,0.0002991861,0.000254682,0.000346344],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5672003,0.02019878,0.07873575,0.0007344324,0.0006280749,0.02452134,0.0003511971,0.0001638751,0.006251007,0.00003366527,0.0007791323,0.3004025],"study_design_scores_gemma":[0.6182477,0.1899136,0.1366908,0.004254101,0.001016546,0.01815966,0.0009659099,0.00528755,0.0095927,0.0003306226,0.01516234,0.0003784304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925685,0.000786212,0.0000408981,0.005006104,0.0004772241,0.001014592,0.00002335177,0.00001562413,0.00006749467],"genre_scores_gemma":[0.9966239,0.001866154,0.0005200288,0.0002776406,0.0005692684,0.00001829982,0.000006451366,0.00003871834,0.00007956656],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.300024,"threshold_uncertainty_score":0.6862506,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08718980111899502,"score_gpt":0.487025124728985,"score_spread":0.39983532360999,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}